pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
P170912J
Phase 3 · small molecule · Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)
P170912J for Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery) is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code P170912J
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)
- Status
- active
- Trials
- 1